CDK4-IN-3

• Description :

  CDK4-IN-3 (Compound 389) is a potent irreversible cyclin-dependent kinase 4 (CDK4) inhibitor (IC50=25 nM, >10-fold selective over CDK6) . CDK4-IN-3 arrests the cell cycle at G₁ phase, and induces tumor cell apoptosis. CDK4-IN-3 is promising for research of solid tumors such as breast and lung cancers[1].

• CAS Number :

  [3002399-75-6]

• UNSPSC :

  12352005

• Target :

  Apoptosis; CDK

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Purity :

  98.07

• Solubility :

  DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  CC(N1C2=CC(C3=NC(N[C@H]4[C@@H](COCC4)O)=NC=C3F)=CC=C2C(C(C)=C1C5CCCN5)=O)C

• Molecular Formula :

  C26H32FN5O3

• Molecular Weight :

  481.56

• References & Citations :

  [1]Jing Li, et al. Substituted 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds as cyclin dependent kinase inhibitors. WO2023208172A1. 2023-11-02.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK4; CDK6